Top

Published in:

01-05-2018 | Original Article

Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage

Authors: Toshiaki Iba, Tatsuhiko Hirota, Koichi Sato, Isao Nagaoka

Published in: International Journal of Hematology | Issue 5/2018

Abstracts

Antithrombin is expected to modulate both prothrombotic and proinflammatory reactions in sepsis; vascular endothelium is the primary target. In the present study, we sought to evaluate the protective effects of a newly developed fucose-deficient recombinant antithrombin. Endothelial cells were treated in vitro with histone H4 to induce cellular damage. Low to high doses of either plasma-derived antithrombin or recombinant thrombomodulin were used as treatment interventions. Morphological change, apoptotic rate, cell viability, cell injury, and syndecan-4 level in the medium were evaluated. Immunofluorescent staining with anti-syndecan-4 was also performed. Both types of antithrombin reduced cellular damage and apoptotic cell death. Both plasma-derived and recombinant antithrombin improved cell viability and reduced cellular injury when administered at a physiological concentration or higher. Syndecan-4 staining became evident after treatment with histone H4, and both antithrombins suppressed the staining intensity at similar levels. The syndecan-4 level in the medium was significantly decreased by both antithrombins. None of the indicators showed a significant difference between plasma-derived and recombinant antithrombin. In conclusion, both recombinant and plasma-derived antithrombin can protect vascular endothelial cells. Recombinant antithrombin may represent a useful new therapeutic agent for sepsis-associated vascular damage.

Available only for authorised users

Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998;38:481–98.CrossRefPubMed

Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol. 2004;36:386–9.CrossRefPubMed

Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115:712–28.CrossRefPubMed

Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253–61.CrossRefPubMed

Franzén LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem. 1980;255:5090–3.PubMed

Mizuochi T, Fujii J, Kurachi K, Kobata A. Structural studies of the carbohydrate moiety of human antithrombin III. Arch Biochem Biophys. 1980;203:458–65.CrossRefPubMed

Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett. 1987;219:431–6.CrossRefPubMed

Turk B, Brieditis I, Bock SC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36:6682–91.CrossRefPubMed

McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol. 2003;326:823–33.CrossRefPubMed

10.

Martínez-Martínez I, Navarro-Fernández J, Østergaard A, Gutiérrez-Gallego R, Padilla J, Bohdan N, et al. Amelioration of the severity of heparin binding antithrombin mutations by posttranslational mosaicism. Blood. 2012;120:900–4.CrossRefPubMed

11.

Fan B, Crews BC, Turko IV, Choay J, Zettlmeissl G, Gettins P. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure. J Biol Chem. 1993;268:17588–96.PubMed

12.

Garone L, Edmunds T, Hanson E, Bernasconi R, Huntington JA, Meagher JL, et al. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry. 1996;35:8881–9.CrossRefPubMed

13.

Olson ST, Frances-Chmura AM, Swanson R, Björk I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch Biochem Biophys. 1997;341:212–21.CrossRefPubMed

14.

Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87:614–22.CrossRefPubMed

15.

Stanley P, Chaney W. Control of carbohydrate processing: the lec1A CHO mutation results in partial loss of N-acetylglucosaminyltransferase I activity. Mol Cell Biol. 1985;5:1204–11.CrossRefPubMedPubMedCentral

16.

Yamada T, Kanda Y, Takayama M, Hashimoto A, Sugihara T, Satoh-Kubota A, et al. Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides. Glycobiology. 2016;26:482–92.CrossRefPubMedPubMedCentral

17.

Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6–11.CrossRefPubMed

18.

Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull. 1996;19:1518–20.CrossRefPubMed

19.

Hirose M, Kameyama S, Ohi H. Characterization of N-linked oligosaccharides attached to recombinant human antithrombin expressed in the yeast Pichia pastoris. Yeast. 2002;19:1191–202.CrossRefPubMed

20.

Schouten M, Wiersinga WJ, Levi M, van Der PT. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536–45.CrossRefPubMed

21.

Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9:121–67.CrossRefPubMed

22.

Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454:345–59.CrossRefPubMedPubMedCentral

23.

Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Iwase M, Yoshikai Y, et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem. 2001;276:47483–8.CrossRefPubMed

24.

Chaaban H, Keshari RS, Silasi-Mansat R, Popescu NI, Mehta-D’Souza P, Lim YP, et al. Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury. Blood. 2015;125:2286–96.CrossRefPubMedPubMedCentral

25.

Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009;83:388–96.CrossRefPubMed

26.

Kaneider NC, Förster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost. 2003;90:1150–7.PubMed

27.

Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res. 2010;87:300–10.CrossRefPubMed

28.

Longley RL, Woods A, Fleetwood A, Cowling GJ, Gallagher JT, Couchman JR. Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci. 1999;112:3421–31.PubMed

29.

Woods A, Couchman JR. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell. 1994;5:183–92.CrossRefPubMedPubMedCentral

30.

Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol. 2010;26:89–114.CrossRefPubMed

31.

Iba T. Glycocalyx regulates the intravascular hemostasis. Juntendo Med J. 2016;62:444–9.CrossRef

32.

De Jong MC, Walstra CM. Immunofluorescent localization of antithrombin III in human skin. Br J Dermatol. 1982;106:281–5.CrossRefPubMed

Title: Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage
Authors: Toshiaki Iba
Tatsuhiko Hirota
Koichi Sato
Isao Nagaoka
Publication date: 01-05-2018
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-018-2402-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstracts

Please log in to get access to this content

Other articles of this Issue 5/2018

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study

Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone

Infusions of Epstein–Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial)

Targeting autophagy in lymphomas: a double-edged sword?

ETV6–ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer